Argenx has agreed to amass Forte Biosciences for $2.2 billion, the businesses stated, in a deal supposed to develop the customer’s immunology portfolio with an early scientific stage candidate that has proven promising knowledge.
Earlier this month Forte introduced constructive outcomes for its lead candidate FB102, from a Section Ib trial assessing the anti-CD122 monoclonal antibody in vitiligo. FB102 achieved a 29.6% imply Facial Vitiligo Space Scoring Index (FVASI) enchancment from baseline at week 24 (p-value = 0.020), with statistically important enhancements seen as early as Day 64 after dosing (p=0.023), persevering with by means of week 24 after completion of the 12-week remedy interval.
FB102 additionally achieved 43.2% imply FVASI enchancment from baseline at week 24 (p-value = 0.006) in topics with larger illness involvement having baseline FVASI ≥0.75 (roughly one-quarter of face depigmented). That share elevated at 58.8% at FVASI50 however fell to 23.5% at FVASI75.
Forte introduced constructive Section Ib knowledge for FB102 final 12 months in celiac illness, with Section II knowledge anticipated to be launched within the second half of this 12 months.
The celiac illness and vitiligo research had been key drivers, Argenx stated, of its determination to go from being a strategic investor in Forte to buying the corporate, for the reason that scientific knowledge covers indications with important unmet want and restricted remedy choices. Argenx was amongst buyers in Forte’s $150 million public providing (5,709,936 shares priced at $26.27), which closed in April.
Pipeline-in-a-product
As with Forte, Argenx causes that FB102 is a pipeline-in-a-product due to its potential to deal with alopecia areata and extra autoimmune illnesses. FB102 provides to Forte’s pipeline a mechanism targeted on pathogenic T-cell and NK-cell exercise, which in accordance with the corporate broadens its means to pursue illnesses pushed by totally different dimensions of the immune system.
“The addition of FB102 to our portfolio aligns completely with the Argenx playbook: compelling biology, sturdy scientific validation and broad potential to deal with affected person want,” Argenx CEO Karen Massey stated in a press release.
Argenx says FB102 enhances its antibody-based portfolio, which is led by marketed medication Vyvgart® (efgartigimod alfa-fcab) injection, indicated to deal with adults with generalized myasthenia gravis (gMG); and Vyvgart Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc), a subcutaneous remedy mixture of the neonatal Fc receptor blocker and endoglycosidase that’s indicated for gMG and power inflammatory demyelinating polyneuropathy (CIDP).
Vyvgart and Vyvgart Hytrulo comprise a blockbuster franchise, having generated $2.813 billion within the first half of this 12 months, up 62% from $1.739 billion in January-June 2025. The franchise racked up $4.151 billion in all of 2025, up 90% from $2.186 billion in 2024.
“The corporate is setting itself up for continued progress past the Vyvgart peak that’s anticipated within the first half of the 2030s,” analysts at Van Lanschot Kempen wrote in a analysis observe, as reported by Bloomberg Information. “All in all, the fitting deal on the proper time.”
40% surge
Forte’s buyers appeared to share that upbeat sentiment, as the corporate’s shares traded on Nasdaq surged about 40% Monday on information of the deal, to $76.50 from $54.78 at Friday’s shut. Argenx’s abnormal shares traded on Euronext Brussels slid 1.8%, to €789.80 ($895.67) from €804.40 ($913.24), whereas American Depositary Shares (ADSs) traded on Nasdaq fell 3%, to $888.82 from $918.22.
Beneath its generic identify, efgartigimod can be being developed for ocular myasthenia gravis (oMG), main immune thrombocytopenia (ITP), Graves’ illness, myositis and associated illnesses (Immune-mediated necrotizing myopathy or IMNM; Antisynthetase syndrome or ASyS; and diabetic myositis); Sjogren’s illness (partnered with IQVIA); systemic sclerosis; and antibody mediated rejection or AMR.
Additionally in Argenx’s pipeline is:
Empasiprubart (previously ARGX-117), designed to be a humanized sweeping antibody that binds particularly to C2 in a pH- and Ca2+-dependent method. Empasiprubart is in registrational research for CIDP and multifocal motor neuropathy (MMN), and in proof-of-concept research for delayed graft perform (DGF).
Adimanebart, a MuSK-targeting candidate in proof-of-concept research for congenital myasthenic syndromes (CMS) and spinal muscular atrophy (SMA).
4 Section I candidates, all with undisclosed indications: ARGX-109 concentrating on IL-6, ARGX-121 concentrating on IgA, ARGX-124 concentrating on FcRn and ARGX-213, which additionally targets FcRn.
Three preclinical candidates: ARGX-118, a Galectin-10 concentrating on candidate for airway irritation; ARGX-125, undisclosed goal and indication; and TSP-101, additionally undisclosed goal and indication.
Buying Forte will construct upon Argenx’s Imaginative and prescient 2030 technique, which units objectives of treating 50,000 sufferers globally with its remedies, securing 10 labeled indications throughout its permitted medicines, and progressing 5 pipeline candidates into Section III improvement, all by 2030.
“Our Imaginative and prescient 2030 technique is well-defined and on observe, and our discovery, improvement and commercialization engines are delivering actual worth for sufferers,” Massey added. “The acquisition of Forte Biosciences builds on the power of that basis and advances our ambition to be the main immunology innovator of the longer term.”
The boards of Argenx and Forte have permitted the transaction, which is predicted to shut within the third quarter.
By an entirely owned subsidiary, Argenx plans to launch a money tender supply to amass all excellent shares of Forte’s widespread inventory at $77 per share money. The deal value represents an roughly 86% premium to Forte Biosciences’ volume-weighted common value (VWAP) since reporting constructive Section Ib knowledge in vitiligo on July 9.
The tender supply is topic to the tender of no less than a majority of the excellent shares of Forte Biosciences, the expiration or termination of the ready interval underneath the Hart-Scott-Rodino Antitrust Enhancements Act of 1976, and different customary closing situations.
Upon profitable completion of the tender supply, an entirely owned subsidiary of Argenx will merge with Forte Biosciences, and the excellent Forte Biosciences shares not tendered within the tender supply shall be transformed into the fitting to obtain the identical $77 per share in money paid within the tender supply.
“We’re extremely pleased with what now we have achieved in advancing FB102 by means of scientific improvement and firmly imagine that Argenx is the perfect strategic accomplice to unlock the complete potential of this novel anti-CD122 antibody throughout a broad vary of autoimmune illnesses,” acknowledged Paul A. Wagner, PhD, Forte’s CEO and chairperson.
“By combining FB102’s promising scientific profile with Argenx’s confirmed improvement experience, international attain and industrial capabilities, now we have a singular alternative to speed up its improvement and maximize its influence for sufferers dwelling with vitiligo, celiac illness, alopecia areata and different autoimmune situations,” Wagner added. “We’re enthusiastic about the way forward for FB102 and the potential to carry this modern remedy to many extra sufferers worldwide.”
